Thermo Fisher Scientific launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as the company engages in more large-scale cohort studies and clinical research.
Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.
